As we work more on the human genome project, the market for rare disease therapies grows, says Nord CEO

CNBC's Meg Tirrell, Nord CEO Peter Saltonstall and Boston Children's Hospital's Dr. Olaf Bodamer join 'Power Lunch' to discuss pharmaceutical companies developing treatments for rare disease, the growth expectations for rare disease pharmaceuticals and the state of competition in the rare disease treatment space.